Geron Corporation
NASDAQ:GERNBiotechnology
+$0.05 today
- Market cap
- $638.38M
- Beta
- 0.60
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.10
Volume 34.97M
Average 16.28M
GERN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Geron CorporationNASDAQ: GERN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $14.96M fell 0.8% year over year, ahead of the -17.7% change in trailing-twelve-month research & development. Sequentially, it fell 5.5% from the prior quarter. Over 3 fiscal years it compounded at -8.3% a year.
Context
- Research & development amounted to 40.1% of revenue in FY2025, down 94.6 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -0.8% holds above the trailing-twelve-month pace of -17.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 73.72M USD
- Year-over-year change
- -28.9%
- 4-year CAGR
- -3.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 73.72M | -28.9% |
| FY2024 | 2024-12-31 | 103.74M | -17.0% |
| FY2023 | 2023-12-31 | 125.05M | +30.9% |
| FY2022 | 2022-12-31 | 95.52M | +11.4% |
| FY2021 | 2021-12-31 | 85.73M | — |
Research & Development vs competitors
How GERN compares with its peers on the latest reported figures
- GERN's LTM Mar 2026 research & development of $73.59M is the 4th highest of the 8 companies compared; the peer median is $59.63M.
- Its year-over-year change of -17.7% is the 5th highest of 7, against a peer median of +25.4%.
- Research & development amounts to 37.5% of revenue for GERN, versus a peer median of 37.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.15B | +9.1% | +8.9% | 37.0% | |
DMRADamora Therapeutics, Inc. | LTM Mar 2026 | $224.29M | +4762.0% | +61.0% | — |
| LTM Mar 2026 | $83.18M | -24.7% | -0.5% | — | |
| LTM Mar 2026 | $73.59M | -17.7% | -8.3% | 37.5% | |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | $59.63M | — | — | — |
| LTM Mar 2026 | $36.54M | +41.7% | -17.9% | 12.2% | |
| LTM Sep 2026 | $23.16M | +47.2% | -19.1% | — | |
| LTM Jun 2026 | $18.74M | -30.0% | -3.0% | 53.4% | |
| Peer median (excluding GERN) | $59.63M | +25.4% | -1.8% | 37.0% | |
Competitors are the stored peer set for GERN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.39M | 596K | 237K | 76.99M | 183.88M |
| Cost of Revenue | 0 | 0 | 0 | 1.26M | 4.75M |
| Gross Profit | 1.39M | 596K | 237K | 75.74M | 179.14M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 98.4% | 97.4% |
| Research & Development | 85.73M | 95.52M | 125.05M | 103.74M | 73.72M |
| Selling, General & Admin | 29.67M | 43.63M | 69.14M | 145.73M | 159.26M |
| Operating Expenses | 115.39M | 139.15M | 194.18M | 249.47M | 232.97M |
| Depreciation & Amortization | 783K | 868K | 1.03M | 1.22M | 1.2M |
| EBITDA | (111.59M) | (134.15M) | (174.78M) | (154.85M) | (51.92M) |
| EBITDA Margin | -8010.7% | -22508.6% | -73747.7% | -201.1% | -28.2% |
| Operating Income | (114M) | (138.55M) | (193.94M) | (173.73M) | (53.84M) |
| Operating Margin | -8183.7% | -23246.6% | -81832.9% | -225.6% | -29.3% |
| Interest Income | 527K | 2.53M | 18.15M | 19.61M | 18.12M |
| Interest Expense | 3.74M | 6.88M | 8.31M | 18.5M | 32.66M |
| Other Income / Expenses | (2.11M) | (3.35M) | 9.82M | (840K) | (31.95M) |
| Income Before Tax | (116.11M) | (141.9M) | (184.13M) | (174.57M) | (85.78M) |
| Pre-Tax Margin | -8335.4% | -23808.9% | -77690.7% | -226.7% | -46.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (116.11M) | (141.9M) | (184.13M) | (174.57M) | (85.78M) |
| Net Margin | -8335.4% | -23808.9% | -77690.7% | -226.7% | -46.7% |
| EPS (Basic) | (0.37) | (0.37) | (0.32) | (0.27) | (0.13) |
| EPS (Diluted) | (0.37) | (0.37) | (0.32) | (0.27) | (0.13) |
| Weighted Avg Shares | 327.63M | 380.78M | 570.65M | 646.03M | 666.66M |
| Weighted Avg Shares (Diluted) | 327.63M | 380.78M | 570.65M | 646.03M | 666.66M |
Geron Corporation
NASDAQ:GERN
Intrinsic Alpha fair value
Locked
Current Price
$0.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.